Page 32 - Read Online

Page 12 of 13 Quartuccio et al. J Cancer Metastasis Treat 2021;7:14 I http://dx.doi.org/10.20517/2394-4722.2020.118

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Asa SL. The current histologic classification of thyroid cancer. Endocrinol Metab Clin North Am 2019;48:1-22.
2. Giovanella L. Thyroglobulin measurement in differentiated thyroid carcinoma management. Expert Rev Endocrinol Metab 2008;3:117-
25.
3. Raue F, Frank-raue K. Long-Term Follow-up in Medullary Thyroid Carcinoma. In: Raue F, editor. Medullary Thyroid Carcinoma. Cham:
Springer International Publishing; 2015. pp. 207-25.
4. Nervo A, Ragni A, Retta F, et al. Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues. J
Endocrinol Invest 2021;44:403-19.
5. Phay JE, Ringel MD. Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr Relat Cancer 2013;20:R307-19.
6. Pacini F, Ito Y, Luster M, Pitoia F, Robinson B, Wirth L. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and
future directions. Expert Rev Endocrinol Metab 2012;7:541-54.
7. Marcus C, Whitworth PW, Surasi DS, Pai SI, Subramaniam RM. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol
2014;202:1316-29.
8. Nanni C, Rubello D, Fanti S, et al. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 2006;60:409-
13.
9. Treglia G, Annunziata S, Muoio B, Salvatori M, Ceriani L, Giovanella L. The role of fluorine-18-fluorodeoxyglucose positron emission
tomography in aggressive histological subtypes of thyroid cancer: an overview. Int J Endocrinol 2013;2013:856189.
10. Dong MJ, Liu ZF, Zhao K, et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-
body scan: a meta-analysis. Nucl Med Commun 2009;30:639-50.
11. Kim SJ, Lee SW, Pak K, Shim SR. Diagnostic performance of PET in thyroid cancer with elevated anti-Tg Ab. Endocr Relat Cancer
2018;25:643-52.
12. Qichang W, Lin B, Gege Z, et al. Diagnostic performance of 18F-FDG-PET/CT in DTC patients with thyroglobulin elevation and
negative iodine scintigraphy: a meta-analysis. Eur J Endocrinol 2019;181:93-102.
13. Lee DY, Kim YI. Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer: A Meta-analysis. Clin Nucl
Med 2020;45:604-10.
14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the
PRISMA statement. PLoS Med 2009;6:e1000097.
15. Campbell I. Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations. Stat Med 2007;26:3661-75.
16. Whiting PF, Rutjes AW, Westwood ME, et al; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic
accuracy studies. Ann Intern Med 2011;155:529-36.
17. Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the Gap between Methodologists and End-Users: R as a
Computational Back-End. J Stat Soft 2012;49.
18. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res
Methodol 2006;6:31.
19. Freudenberg LS, Frilling A, Kühl H, et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative
differentiated thyroid cancer. Eur Radiol 2007;17:3139-47.
20. Klain M, Nappi C, Nicolai E, et al. Comparison of simultaneous F-2-[18F] FDG PET/MR and PET/CT in the follow-up of patients with
18
differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2020;47:3066-73.
21. Kundu P, Lata S, Sharma P, Singh H, Malhotra A, Bal C. Prospective evaluation of (68)Ga-DOTANOC PET-CT in differentiated thyroid
cancer patients with raised thyroglobulin and negative (131)I-whole body scan: comparison with (18)F-FDG PET-CT. Eur J Nucl Med
Mol Imaging 2014;41:1354-62.
22. Leboulleux S, El Bez I, Borget I, et al. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission
tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid 2012;22:832-8.
18
23. Nagamachi S, Wakamatsu H, Kiyohara S, et al. Comparison of diagnostic and prognostic capabilities of F-FDG-PET/CT,
¹³¹I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer. Jpn J Radiol 2011;29:413-22.
24. Nakajo M, Nakajo M, Jinguji M, et al. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between
FDG and FLT PET/CT studies. Radiology 2013;267:891-901.
18
18
25. Ota N, Kato K, Iwano S, et al. Comparison of F-fluoride PET/CT, F-FDG PET/CT and bone scintigraphy (planar and SPECT) in
detection of bone metastases of differentiated thyroid cancer: a pilot study. Br J Radiol 2014;87:20130444.
26. Piccardo A, Foppiani L, Morbelli S, Bianchi P, Barbera F, Biscaldi E, Altrinetti V, Villavecchia G, Cabria M. Could [18]
F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan? Q J
Nucl Med Mol Imaging 2011;55:57-65